Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Phase 1 Study of Ulixertinib (BVD 523) in Patients with Advanced Solid Malignancies

ABSTRACT: Phase 1 Study of Ulixertinib (BVD 523) in Patients with Advanced Solid Malignancies

PROVIDER: PRJNA882457 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR21659583.fastq.gz	Fastqsanger.gz
	SRR21659584.fastq.gz	Fastqsanger.gz
	SRR21659585.fastq.gz	Fastqsanger.gz
	SRR21659586.fastq.gz	Fastqsanger.gz
	SRR21659587.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 14

Similar Datasets

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

Project description:The objective of this expanded access program is to provide ulixertinib (BVD-523) for compassionate use in advanced cancer patients with MAPK pathway-altered solid tumor(s), including but not limited to KRAS, NRAS, HRAS, BRAF, MEK, and ERK mutations who have incomplete response to or have exhausted available therapies. Ulixertinib is available for treatment as monotherapy or in combination with other clinically tolerable agent(s), conditionally approved by the drug manufacturer.

| 2352905 | ecrin-mdr-crc

Phase 1 Study Combining Alisertib with Nab-Paclitaxel in Patients with Advanced Solid Malignancies (NCT01677559)

Project description:Phase 1 Study Combining Alisertib with Nab-Paclitaxel in Patients with Advanced Solid Malignancies (NCT01677559)

| PRJNA731485 | ENA

Phase 1 Study of Ulixertinib (BVD 523) in Patients with Advanced Solid Malignancies

Project description:RNAseq from tumor samples of patients treated on clinical trial

2023-02-15 | GSE213797 | GEO

Immuno-Transcriptomic Profiling Identifies Actionable Alterations in Pediatric Solid Malignancies

Project description:Immuno-Transcriptomic Profiling Identifies Actionable Alterations in Pediatric Solid Malignancies

2021-12-07 | PXD017130 | Pride

An Integrative Proteome-Based Pharmacologic Characterization and Therapeutic Strategy Exploration of SAHA in Solid Malignancies

Project description:An Integrative Proteome-Based Pharmacologic Characterization and Therapeutic Strategy Exploration of SAHA in Solid Malignancies.

2021-12-07 | PXD030220 |

Advanced Genetic and Molecular Analysis of Solid Tumors

Project description:Advanced Genetic and Molecular Analysis of Solid Tumors

| PRJNA615693 | ENA

Advanced Genetic and Molecular Analysis of Solid Tumors

Project description:Advanced Genetic and Molecular Analysis of Solid Tumors

| PRJNA615692 | ENA

Spatial coupling of microbes and immune cells in solid malignancies

Project description:Spatial coupling of microbes and immune cells in solid malignancies

| PRJNA655408 | ENA

Spatial coupling of microbes and immune cells in solid malignancies.

Project description:Spatial coupling of microbes and immune cells in solid malignancies.